Paediatric Committee
The Paediatric Committee (PDCO) is responsible for providing scientific opinions on the development of medicines for use in children, in accordance with the Reguation (EC) 1901/2006. The main responsibility of the PDCO is to assess the content of paediatric investigation plans and adopt opinions on them. This includes the assessment of applications for a full or partial waiver and assessment of applications for deferrals.
The meeting involves the participation of representatives from the National Competent Authorities (NCA’s), including European Economic Area Competent Authorities (Iceland, Norway and Liechtenstein), the European Commission and the European Medicines Agency.
The PDCO holds monthly meetings, except for the month of August, at the premises of the European Medicines Agency, based in London. Informal meetings can be organized by the Member State holding the Presidency of the Council of the European Union.
An informal meeting of the PDCO will be held on 30 September – 01 October (Antwerp) during the Belgian Presidency. Joint meetings with the Committee for Medicinal Products for Human Use, the Committee for Orphan Medicinal Products, the Paediatric Committee, the Committee for Advanced Therapies and the Scientific Advice Working Party are foreseen.